Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024
H1N1 nanobody development and therapeutic efficacy verification in H1N1-challenged mice.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hwang Jaehyun, Jang In-Young, Bae Eunseo, Choi Jaeseok, Kim Jeong Hwan, Lee Sang Beum, Kim Jong Hyun, Lee Jae Pil, Jang Ho Young, Kim Hyoung Tae, Lim Jong-Woo, Yeom Minjoo, Jang Eunhee, Kim Seong-Eun, Jeong Hyoung Hwa, Kim Jung Woo, Seong Seung-Yong, Song Daesub, Na Woonsung
Аннотация
Influenza A virus causes numerous deaths and infections worldwide annually. Therefore, we have considered nanobodies as a potential treatment for patients with severe cases of influenza. We developed a nanobody that was expected to have protective efficacy against the A/California/04/2009 (CA/04; pandemic 2009 flu strain) and evaluated its therapeutic efficacy against CA/04 in mice experiments. This nanobody was derived from the immunization of the alpaca, and the inactivated CA/04 virus was used as an immunogen. We successfully generated a nanobody library through bio-panning, phage ELISA, and Bio-layer interferometry. Moreover, we confirmed that administering nanobodies after lethal doses of CA/04 reduced viral replication in the lungs and influenza-induced clinical signs in mice. These research findings will help to develop nanobodies as viral therapeutics for CA/04 and other infectious viruses.